title: [Metabolic syndrome: from insulin resistance to adipose tissue dysfunction].
abstract: Recently the definition, the pathophysiology and even the clinical utility of metabolic syndrome (MS) have been discussed. The risk induced by each component of the metabolic syndrome is higher than the risk induced by MS alone. MS alone is, in fact, a weaker predictor of cardiovascular disease than diabetes. New criteria to define the metabolic syndrome have been proposed, as adipokines, CRP and PAI-1. IGFBP-1 is related to hyperinsulinemia/insulin resistance and to the risk of diabetes and fatal ischemic heart disease development. IGF/IGFBP system could be a link between insulin resistance and cardiovascular disease. RBP-4 can attenuate insulin signalling in skeletal muscle and induce hepatic gluconeogenesis. The belief that insulin-resistance is the main cause of MS could change in favour of the adipose tissue dysfunction. The most common cause of a reduced capacity of the adipose tissue to store fats is the increased dietary intake, also present in lipodistrophy, type 1 diabetes mellitus and polycystic ovarian syndrome. The adipose tissue production of adipokines and cytokines (such as IL-6, TNF-alpha and TGF-beta) and the excessive lipid flux towards muscles, heart and liver (Ectopic fat storage syndrome) contribute to the MS genesis and to an increased cardiovascular risk. The comprehension of adipose tissue dysfunction mechanisms offers new possibilities of prevention and therapy.
authors.affiliation: Cattedra di Semeiotica e Metodologia Medica, Dipartimento di Medicina Interna, Malattie Cardiovascolari e Nefrourologiche, Università di Palermo, Palermo, Italia.
authors.forename: A
authors.initials: A
authors.lastname: Camera
authors.forename: E
authors.initials: E
authors.lastname: Hopps
authors.forename: G
authors.initials: G
authors.lastname: Caimi
mesh_terms: D052242:Adiponectin / Q000502:physiology; D000273:Adipose Tissue / Q000378:metabolism* / Q000503:physiopathology; D002097:C-Reactive Protein / Q000502:physiology; D006801:Humans; D007333:Insulin Resistance; D018969:Insulin-Like Growth Factor Binding Proteins / Q000502:physiology; D015850:Interleukin-6 / Q000502:physiology; D020738:Leptin / Q000502:physiology; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000502:physiology; D016160:Retinoblastoma Protein / Q000502:physiology; D009626:Terminology as Topic
chemical_list: D052242:Adiponectin; D018969:Insulin-Like Growth Factor Binding Proteins; D015850:Interleukin-6; D020738:Leptin; D017395:Plasminogen Activator Inhibitor 1; D016160:Retinoblastoma Protein; D002097:C-Reactive Protein